Synthesis, X-ray structure, DFT and antimicrobial studies of Ag(I) complexes with nicotinic acid derivatives

Polypyridyl ruthenium complexes with benzothiazole moiety as membrane disruptors and anti-resistance agents for Staphylococcus aureus

Developing new antimicrobials to combat drug-resistant bacterial infections is necessary due to the increasing problem of bacterial resistance. In this study, four metallic ruthenium complexes modified with benzothiazoles were designed, synthesized and subjected to bio-evaluated. Among them, Ru-2 displayed remarkable inhibitory activity against Staphylococcus aureus (S. aureus) with a minimum inhibitory concentration (MIC) of 1.56 μg/mL. Additionally, it showcased low hemolytic toxicity (HC50 > 200 μg/mL) and the ability to effectively eradicate S. aureus without fostering drug resistance. Further investigation into the antibacterial mechanism suggested that Ru-2 may target the phospholipid component of S. aureus, leading to the disruption of the bacterial cell membrane and subsequent leakage of cell contents (nucleic acid, protein, and ONPG), ultimately resulting in the death of the bacterial cell. In vivo studies, both the G. mellonella larvae and the mouse skin infection models were conducted, indicated that Ru-2 could potentially serve as a viable candidate for the treatment of S. aureus infection. It exhibited no toxic or side effects on normal tissues. The results suggest that benzothiazole-modified ruthenium complexes may have potential as membrane-active antimicrobials against drug-resistant bacterial infections.

Synthesis, X-ray Structure, Antimicrobial and Anticancer Activity of a Novel [Ag(ethyl-3-quinolate)2(citrate)] Complex

A novel Ag(I) citrate complex with ethyl-3-quinolate (Et3qu) was synthesized. Its structure was confirmed using X-ray single crystal to be [Ag(Et3qu)2(citrate)]. It crystallized in the Triclinic crystal system and P-1 space group with unit cell parameters of a = 8.6475(2) Å, b = 11.4426(3) Å, c = 15.2256(3) Å, α = 73.636(2)°, β = 79.692(2)° and γ = 86.832(2)°, while the unit cell volume was 1422.19(6) Å3. In the unit cell, there are two [Ag(Et3qu)2(citrate)] molecules and one unit as the asymmetric formula. The molecular structure comprised one Ag(I) coordinated with two Et3qu molecules via two almost equidistant Ag-N bonds and one citrate ion acting as a mono-negative monodentate ligand via a short Ag-O bond (2.5401(14) Å). Hence, Ag(I) is tri-coordinated and has a highly distorted triangular planar coordination geometry which is more like to be described as a slightly distorted T-shape. The supramolecular structure of the [Ag(Et3qu)2(citrate)] complex was analyzed using Hirshfeld calculations. The H···H (39.3–40.1%), O···H (33.2-34.0%), C···C (9.1–9.5%) and C···H (7.2–7.4%) contacts shared significantly in the packing of the studied Ag(I) complex. The antimicrobial and anticancer activities of the Ag(I) complex were investigated. The [Ag(Et3qu)2(citrate)] complex has broad-spectrum antimicrobial activity specifically against the fungus A. fumigatus. In addition, the IC50 values of 1.87 ± 0.09 µg/mL and 0.95 ± 0.06 µg/mL against the breast MCF-7 and lung A-549 cell lines, respectively, revealed the potent anticancer activity of the [Ag(Et3qu)2(citrate)] complex compared to the free Et3qu (IC50 = 30.64 ± 1.98 and 22.89 ± 1.48 µg/mL, respectively).

Preparation and properties of a dual-function cellulose nanofiber-based bionic biosensor for detecting silver ions and acetylcholinesterase

A dual-function cellulose nanofiber (CNF)-based bionic biosensor with good biocompatibility was developed for detecting Ag⁺ and acetylcholinesterase (AChE) by grafting deoxyribonucleic acid (DNA) onto CNF. The Ag⁺ ions captured by the biosensor acted as recognition sites for the detection of AChE. The CNF-based bionic biosensor (CNF-DNA) could detect Ag⁺ concentrations as low as 10^-6 nM in the presence of interference metal ions (Hg²⁺, Ba²⁺, Cd²⁺, Mg²⁺, Mn²⁺, Pb²⁺, and Zn²⁺). DNA-template silver nanoclusters (DNA-AgNCs) were formed on the surface of CNF-DNA during the detection of Ag⁺ (CNF-DNA-AgNCs). This new strategy yielded CNF-DNA-AgNCs through the adsorption of Ag⁺ ions onto the cytosine base of the single-stranded DNA in CNF-DNA without the use of any additional reducer. Meanwhile, the CNF-DNA-AgNCs exhibited excellent sensitivity and selectivity for trace levels (0.053 mU/mL) of AChE in the presence of interference reagents. The novel strategy proposed in this paper may establish a foundation for further research on DNA-template AgNCs for developing biosensors and biomarkers for in vivo and in vitro detection.

Silver(i) complexes with different pyridine-4,5-dicarboxylate ligands as efficient agents for the control of cow mastitis associated pathogens

Infections of the cow udder leading to mastitis and lower milk quality are one of the biggest problems in the dairy industry worldwide. Unfortunately, therapeutic options for the treatment of cow mastitis are limited as a consequence of the development of pathogens that are resistant to conventionally used antibiotics. In the search for agents that will be active against cow mastitis associated pathogens, in the present study, five new silver(i) complexes with different chelating pyridine-4,5-dicarboxylate types of ligands, [Ag(NO₃)(py-2py)]_n (1), [Ag(NO₃)(py-2metz)]_n (2), [Ag(CH₃CN)(py-2py)]BF₄ (3), [Ag(py-2tz)₂]BF₄ (4) and [Ag(py-2metz)₂]BF₄ (5), py-2py is dimethyl 2,2'-bipyridine-4,5-dicarboxylate, py-2metz is dimethyl 2-(4-methylthiazol-2-yl)pyridine-4,5-dicarboxylate and py-2tz is dimethyl 2-(thiazol-2-yl)pyridine-4,5-dicarboxylate, were synthesized, structurally characterized and assessed for in vitro antimicrobial activity using both standard bioassay and clinical isolates from a contaminated milk sample obtained from a cow with mastitis. These complexes showed remarkable activity against the standard panel of microorganisms and a selection of clinical isolates from the milk of the cow diagnosed with mastitis. With the aim of determining the therapeutic potential of silver(i) complexes, their toxicity in vivo against the model organism, Caenorhabditis elegans (C. elegans), was investigated. The complexes that had the best therapeutic profile, 2 and 5, induced bacterial membrane depolarization and the production of reactive oxygen species (ROS) in Candida albicans cells and inhibited the hyphae as well as the biofilm formation. Taken together, the presented data suggest that the silver(i) complexes with pyridine ligands could be considered for the treatment of microbial pathogens, which are causative agents of cow mastitis.

A bioactivity-oriented modification strategy for SDH inhibitors with superior activity against fungal strains

In this work, a total of 36 novel 5-(nicotinamido)-1-phenyl-1H-pyrazole-4-carboxylic acid derivatives were designed and synthesized successfully by introducing a carboxyl group based on the N-(1-(4-chlorophenyl)-4-cyano-1H-pyrazol-5-yl)-6-methoxynicotinamide. Among them, the growth inhibition assays on agar plates showed that compound 5IV-d(5-(2-chloronicotinamido)-1-(p-tolyl)-1H-pyrazole-4-carboxylic acid) exhibited the significant antifungal activity against four important fruit and main crop disease fungi (i.e., Valsa mali Miyabe et Yamada, Botryosphaeria dothidea, Helminthosporium maydis and Rhizoctonia cerealis) with EC₅₀ values of 22.6, 14.5, 17.6 and 18.2 μM, respectively. In addition, 5IV-d showed the excellent inhibitory effect against SDH enzymes with IC₅₀ values ranging from 9.4 to 15.6 μM. In vivo bioassay and molecular docking were applied to explore the potential in practical application and combination of modified structure and SDH. The results of structure-activity relationships indicates that the methoxy substitution at the benzene ring attached to the pyrazole ring and a wide variety of substituents could be responsible for the promising antifungal efficacy of the designed compounds. This study demonstrated that the compound 5IV-d can act as the most potent SDH inhibitor in the reported series of compounds.